HealthcareServices

Systemic Aspergillosis And Systemic Candidiasis Market Outlook 2026–2035: Growth Drivers and Industry Forecast

March 3, 2026March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the systemic aspergillosis and systemic candidiasis market from 2026–2035 with trusted insights from The Business Research Company

How is the Systemic Aspergillosis And Systemic Candidiasis Market size predicted to change over the forecast window of 2026–2035?

The market size for systemic aspergillosis and systemic candidiasis has experienced steady growth in recent years. It is projected to increase from $7.57 billion in 2025 to $7.94 billion in 2026, registering a compound annual growth rate (CAGR) of 4.9%. The growth observed during the historic period can be attributed to a rise in immunocompromised patient populations, an increasing prevalence of invasive fungal infections, the availability of azole and amphotericin formulations, the expansion of hospital intensive care units, and enhanced diagnostic awareness.

The market size for systemic aspergillosis and systemic candidiasis is projected to experience substantial expansion over the coming years. This market is anticipated to reach $9.76 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.3%. Several factors will drive this growth during the forecast period, including the accelerating development of new antifungal agents, a heightened emphasis on managing antifungal resistance, the proliferation of targeted antifungal treatments, increasing financial commitments to infectious disease research, and the wider uptake of combination therapy approaches. Key trends foreseen in the forecast period encompass a greater embrace of cutting-edge antifungal treatments, an increased emphasis on the prompt detection of systemic fungal infections, the broadening scope of combination antifungal therapy strategies, a surging need for critical care antifungals within hospitals, and improved surveillance of drug resistance profiles.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12148&type=smp

Which Drivers Are Contributing To The Expansion Of The Systemic Aspergillosis And Systemic Candidiasis Market?

The anticipated rise in the prevalence of fungal diseases is expected to propel the growth of the systemic aspergillosis and systemic candidiasis market in the coming years. Fungal diseases are defined as infections caused by fungi that can impact various parts of the body, leading to diverse symptoms and complications. These conditions include cutaneous skin infections, respiratory infections, and systemic infections. Antifungal medications, such as oral azoles, voriconazole, and liposomal amphotericin B, are used to treat fungal diseases. For instance, in 2023, the Uk Health Security Agency, a UK-based government agency, reported that the rate of yeast-related bloodstream infections across England increased by 4% compared to 2022. Thus, the escalating incidence of fungal disease is a key driver for the expansion of the systemic aspergillosis and systemic candidiasis market.

What Segment Categories Are Covered In The Systemic Aspergillosis And Systemic Candidiasis Market?

The systemic aspergillosis and systemic candidiasis market covered in this report is segmented –

1) By Type: Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Other Types

2) By Application: Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Pulmonary Aspergillosis (CPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other Applications

3) By End User: Clinic, Hospital, Other End Users

Subsegments:

1) By Systemic Oral Azoles: Fluconazole, Itraconazole, Posaconazole, Voriconazole

2) By Voriconazole: Voriconazole Tablets, Voriconazole Injection

3) By Liposomal Amphotericin B: Liposomal Amphotericin B For Systemic Aspergillosis, Liposomal Amphotericin B For Systemic Candidiasis

4) By Topical Antifungal Agents: Topical Azoles, Topical Polyenes, Topical Allylamines

5) By Other Types: Echinocandins, Antifungal Combination Therapies, Other Emerging Antifungal Agents

Which Innovation Trends Are Advancing Developments Within The Systemic Aspergillosis And Systemic Candidiasis Market?

Leading companies operating within the systemic aspergillosis and systemic candidiasis markets are actively focusing on creating advanced products, such as echinocandins, to bolster treatment effectiveness and confront the escalating issues of antifungal resistance. Echinocandins are a category of antifungal medications that work by preventing the formation of β-glucan, an essential part of the fungal cell wall. For instance, in March 2023, Cidara Therapeutics, a US-based biotechnology company, alongside Melinta Therapeutics, also a US-based biotechnology company, obtained approval from the Food and Drug Administration (FDA), a US-based federal agency responsible for safeguarding public health, for REZZAYO (rezafungin for injection). REZZAYO (rezafungin for injection) is an innovative once-weekly echinocandin intended for the treatment of candidemia in adults who have restricted or no other treatment options. Designed for ease of use, REZZAYO’s once-weekly dosing schedule simplifies therapy and improves the consistency of care for patients suffering from invasive candidiasis, proving especially useful in hospital environments where managing such infections effectively is crucial.

Which Key Market Players Are Investing In Expansion And Innovation Within The Systemic Aspergillosis And Systemic Candidiasis Market?

Major companies operating in the systemic aspergillosis and systemic candidiasis market are Pfizer Inc, Merck & Co. Inc, AbbVie Inc, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A, GlaxoSmithKline PLC, Gilead Sciences Inc, Astellas Pharma Inc, Matinas BioPharma Holdings Inc, Shionogi & Co. Ltd, Cipla Limited, Basilea Pharmaceutica Ltd, Cidara Therapeutics Inc, Entasis Therapeutics Inc, F2G Ltd, Mycovia Pharmaceuticals Inc, ContraFect Corporation, Enzon Pharmaceutical Inc, Pacgen Life Science Corporation, Biosergen AS

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/systemic-aspergillosis-and-systemic-candidiasis-global-market-report

Which Regions Are Poised For Strategic Growth In The Systemic Aspergillosis And Systemic Candidiasis Market?

North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic aspergillosis and systemic candidiasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Systemic Aspergillosis And Systemic Candidiasis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12148&type=smp

Browse Through More Reports Similar to the Global Systemic Aspergillosis And Systemic Candidiasis Market 2026, By The Business Research Company

Invasive Fungal Infections Market Report 2026

https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report

Aspergillosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/aspergillosis-treatment-global-market-report

Candidiasis Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795